The hepatitis C cascade of care for opioid agonist therapy recipients in **ACCESS** participating clinics in Australia.

Samara Griffin^{1,2,3}, Jason Asselin¹, Anna L Wilkinson^{1,2,4}, Basil Donovan⁵, Rebecca Guy⁵, Wayne Dimech⁶, Alexander Thompson^{3,7}, Rebecca Winter^{1,2,3}, Michael Traeger¹, Matthew Penn⁸, Alisa Pedrana¹, Margaret Hellard ^{1,2,5,9}, Mark Stoové^{1,2,10,} on behalf of the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of sexually transmissible infections and blood-borne viruses (ACCESS).

1 Disease Elimination, Burnet Institute, Melbourne, VIC, Australia, 2 School of Public Health and Preventive Medicine, VIC, Australia, 3 Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC, Australia, 4 University of Melbourne School of Population and Global Health, Melbourne, VIC, Australia, 5 Kirby Institute, University of New South Wales, Sydney, NSW, Australia, 7 Department of Medicine, University of Melbourne, VIC, Australia, 8 North Richmond Community Health, Melbourne, VIC, Australia, 9 Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Australia, 10 Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, VIC, Australia.

BACKGROUND

- People prescribed opioid agonist therapy (OAT) are a key population for hepatitis C virus elimination.
- Health service engagement associated with OAT provision may facilitate HCV testing and treatment.
- ACCESS is a sentinel, national health surveillance network for monitoring, testing, treatment, and management of BBVs and STIs.

PATIENT FLOW CHART





Figure 1. Patient flow chart through hepatitis C testing and treatment, ACCESS, Australia, 2016–2023, N=15,382. Data includes observed and inferred data. Denominators for percentage calculations are the number of participants at the

We aim to quantify the testing and treatment cascade among people receiving OAT in Australia.


METHODS

We extracted linked data from individuals attending primary and sexual health clinics in the ACCESS surveillance network from 2016 to 2023.

We estimated the number of individuals at each stage of the following cascade by the end of the study period:




Individuals enter the cascade at the date of their first OAT prescription.



Individuals with an observed positive RNA were inferred as antibody positive, and individuals with an observed DAA prescription were inferred as RNA and antibody positive.

We calculated total time in the cascade, defined as time (days) between the first observed positive HCV antibody test and DAA prescription.



- 81% of all individuals were treated within a year of first testing RNA positive (1327/1637)
- The proportion treated within a year of first testing RNA positive increased from 74% in 2016 (491/661) to 100% in 2022 (46/46) and 2023 (22/22).

CONCLUSION

- A high proportion of people prescribed OAT were not engaged in care by their OAT provider or across the ACCESS network.
- Once diagnosed, retention in care is high among those

Figure 2: The hepatitis C cascade of care among individuals with at least one electronic prescription for OAT, ACCESS, Australia, 2016–2023, N=4,368

prescribed OAT, with 94% of HCV antibody positives being RNA tested.

- The median total time in the cascade decreased from 2016 to 2022, indicating is improving.
- Given the high prevalence of antibody and RNA positivity among those tested, integrating HCV care into regular OAT care should be a priority for elimination.

Burnet reach for the many

¹Samara Griffin, Burnet Institute, Melbourne, Australia email: samara.griffin@student.burnet.edu.au

burnet.edu.au